Skip to main content
MSGR logo

MSG Rangers Corp Class A (MSGR) Fund Overview

MSG Rangers Corp Class A (MSGR) — price $254.55 (+2.14%), as of the Nov 20, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$254.55 +$5.34 (+2.14%)

MSG Rangers Corp Class A · MSGR · NYSE

Direxion mRNA ETF (MSGR) aims to track the performance of companies leading the development and application of messenger RNA (mRNA) technology. The fund invests primarily in publicly listed companies in the United States, Canada, and Europe.

Price as of Nov 20, 2026

Key Statistics

Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • NFLX · Netflix, Inc. · 94 /100
  • DIS · The Walt Disney Company · 76 /100
  • LYV · Live Nation Entertainment, Inc. · 59 /100

See all scored stocks →

Price & valuation

As of
MeasureValue
Latest provided price$254.55
Change on the day+2.14%
52-week range$176.00 – $254.55
Shares traded on the day226.9K

Price & events

1 · What is it?

What is MSG Rangers Corp Class A (MSGR), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. MSG Rangers Corp Class A (MSGR) is listed on NYSE. It employs 147 people and is led by James L. Dolan. In Q1 FY2026 it reported revenue of $14M and net income of -$17M.

2 · Latest results

What do the latest results show for MSG Rangers Corp Class A (MSGR)?

Short answer · as of

The most recent reported quarter, Q1 FY2026, carried revenue of $14M.

Quarterly income statement — 1 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2026$14M-$17M-$1.40 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for MSG Rangers Corp Class A (MSGR)?

Short answer · as of

Trailing ratios: ROA -4.2% · current ratio 0.52 · earnings yield -0.9% · free-cash-flow yield -2.2%.

4 · What to check next?

What should you watch next at MSG Rangers Corp Class A (MSGR)?

Short answer · as of

Analyst estimates on file carry FY2027 revenue $352.15M · EPS -3.91 · 3 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No Altman Z or Piotroski screen is held for this filer.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$352.15M
EPS estimate
$-3.91

Measured against a quoted price of $254.55 (as of Nov 20, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MSGR in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MSGR in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

MSG Rangers Corp Class A Stock: Key Questions Answered

These answers are editorial: 1 of these 1 answer is drawn from the MSGR research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What do analysts say about MSGR stock?

However, the fund's performance is closely tied to the overall sentiment and growth prospects of the mRNA technology sector. Investors should monitor industry news, clinical trial results, and regulatory developments to assess the potential risks and rewards associated with MSGR.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.